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Research interests on radiosensitive property of gold nanoparticles (GNPs) are rapidly raised because of the extensively
proved in vitro effectiveness and clinical necessity. However, the issue of targeted accumulation of GNPs in tumor tissues
hindered the transference to in vivo applications. In this study, hybrid nano-sized cyclic Arg-Gly-Asp-conjugated GNPs
(cRGD-GNPs) integrated with radioactive iodine-125 was fabricated as tumor-targeted radiosensitizer. Therapeutic
effects, including acute apoptosis (2 days post treatment) and long-term influence (up to 21 days), were investigated
on NCI-H446 tumor-bearing mice via Tc-99 m-Annexin V SPECT and volume measurements, respectively.
Apoptosis and volume loss were consistent in showing that tumor growth was effectively suppressed via the
treatment of 125I-cRGD-GNP sensitized radiotherapy (RT), a more significantly radiosensitive effect than the
treatment of non-targeted GNPs with RT, RT treatment alone, and no treatment. SPECT/CT images showed that
the uptake of cRGD-GNPs by tumor tissues reached the peak target/non-target value of 4.76 at around 2 h post
injection, and dynamic radioactivity monitoring showed that 125I-cRGD-GNPs maintained about 2.5% of injected
dosage at 55 h post injection. For long-term influence, a significant radiosensitized RT-induced volume loss was
observed. Hence, cyclic RGD conjugation makes the GNP-based radiosensitizer tumor targeting, offering a new
modality for enhancing radiotherapeutic efficacy. Additionally, the introduction of I-125 serves as both a therapeutic factor
and a radiotracer for in vivo tracking of GNPs.
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Surface plasmon resonance and the ability to bind thiol
and amine group enabled the biological and medical ap-
plications of gold nanoparticles (GNPs) [1], such as
photodynamic therapy [2], therapeutic delivery agents
[3], diagnostic agents [4,5], and radiosensitizer [6,7]. Re-
markably, research on radiosensitive properties of gold
nanoparticles and corresponding mechanism has got a
lot of progress. In general, dose enhancement factor
(DEF) related to radiosensitive effect ranges from 1.01 to
2.11 [8], depending on various items, such as the dosage
of radiation, concentration, size, morphology, surface
coating, and charging of radiosensitizer. For radiation
energy, kV radiotherapy (RT) carries higher DEF than
MV energy [9] but is limited to superficial tumors be-
cause of the weak penetrability. For tumor targeting,* Correspondence: suningresearch@126.com
1Department of Radiation Oncology, Tianjin Medical University Cancer
Institute and Hospital, National Clinical Research Center of Cancer, Key
Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
Full list of author information is available at the end of the article
© 2015 Su et al.; licensee Springer. This is an O
Attribution License (http://creativecommons.or
in any medium, provided the original work is pGNPs may passively accumulate in tumor tissues due to
enhanced permeability and retention (EPR) effect of im-
mature blood vessels, but target molecules, such as anti-
bodies, could promote active targeting process, where an
interaction of cell membrane and target molecules on
the surface existed. On the other side, size and morph-
ology influence the cellular uptake and cytotoxicity. As a
general rule, a diameter of less than 30 nm is deemed as
necessary for adequate cellular import [10], but smaller
GNPs bring bigger toxicity [11,12]. The uptake of
shorter rod-shaped GNPs is higher than that of longer
ones, but both are lower than spherical ones [13]. On
the contrary, rod-shaped GNPs were exocytosed faster
than spherical ones because of the relatively less conju-
gated binding factors [14]. For in vivo applications,
besides EPR effect, reticuloendothelial system (RES) also
heavily influences the in vivo distribution of nano-sized
radiosensitizer. Smaller size is helpful in avoiding the
RES uptake [15]. Moreover, polyethylene glycol (PEG)
coating is effective to reduce the RES uptake andpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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of GNP amount in tumor (10- to 100-folds, compared to
nude GNPs) [16,17] and less spleen and liver damage
[18]. Hence, compromises among these items above are
considerable for practical applications.
Radiosensitive property, reflected as drug efficacy, is
heavily influenced by targeting efficiency. The αβ serial
integrins in regulation of angiogenesis is one of the most
promising and best studied targets in oncology research
[19]. Correspondingly, Arg-Gly-Asp (RGD)-based strat-
egy to target αvβ3 integrin, which mediates various can-
cer stages, such as malignant transformation, tumor
growth and progression, invasion, and metastasis, is
most researched in cancer diagnosis and therapy. Conju-
gation of RGD peptides enables drugs to recognize αvβ3
integrin, abundantly expressed on tumor blood vessels
but not on vessels of normal tissues [20]. Therefore, lots
of RGD-based αvβ3-targeted drugs, including hybrid
nanoparticles, have been designed as therapy drug, drug
delivery system, imaging agent, and complex functional-
ized drugs. Chemotherapeutics, such as doxorubicin, has
been loaded by RGD-based nanoparticles [21]; moreover,
the more complex ‘all-in-one’ RGD-based magnetic nano-
particles, which contained iron oxides as contrast agent,
siRNA as therapeutic agent, and a fluorescent dye for fluor-
escent microscopy, were designed and evaluated in vitro
[22]. Particularly, RGD-conjugated gold nanoparticles were
reported and tested for targeting efficiency and radiosensiti-
zation as well, but in vitro evaluation was rarely reported
[23]. Overall, the targeting of RGD-grafted nanoparticles to
tumoral endothelium was more effective than non-targeted
nanoparticles [24,25]. Additionally, safety profiles and no-
dose-limiting toxicity proved in patients are more advan-
taged than antibody strategies [26,27]. Hence, RGD-based
strategy provides a promising and efficient approach in
guiding the GNPs.
Herein, we chose the 20-nm GNPs as the platform for
constructing the multifunctional agent. Cyclic RGDyC
peptides were chosen considering the rigidity and variety
of chemical modification. In order to evaluate the in vivo
targeting efficiency and RT effect of the targeting radio-
sensitizer, human small-cell lung cancer model, NCI-
H446 tumor cell-bearing mice model, was utilized due
to the relatively moderate sensitivity to RT and the
clinical needs. For the assessment of RT effect, Tc-99
m-Annexin V SPECT was utilized in early evaluation of
apoptosis induced by radiosensitized RT for the first
time and cooperated with tumor volume measurements,
guaranteeing the consistency of acute apoptosis assess-
ment and long-term observation of therapeutic effect. In
this study, radionuclide was also introduced in fabrica-
tion of radiosensitizer. Iodine-125 was labeled to the
cRGD-GNPs and delivered an effective radiation dose to
tumor cells with minimal damage to normal tissues [28].As a clinically used therapeutic radionuclide, I-125
contributes to the radiotherapy effect; even more
importantly, I-125 provides an approach of in vivo dy-
namic monitoring to figure out biodistributions of
cRGD-GNPs.Methods
Materials and instruments
The following instruments were used: cobalt-60 radio-
active point source, NanoSPECT/CT (Bioscan, Washing-
ton, DC, USA); radioactivity meter (CRC-25R, Capintec
Inc., Ramsey, NJ, USA); centrifuge (80–1, Zhengzhou Boke
Instrument Equipment Co., Ltd., Henan, China); transmis-
sion electron microscope (TEM; 2100 F, JEOL Ltd., Tokyo,
Japan); and zetasizer Nano (ZSP, Malvern Instruments Ltd.,
Worcestershire, UK).
The following materials and reagents were used:
1,3,4,6-tetrachloro-3a,6a-diphenylglucoluril (Iodogen) and
4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid 3-
sulfo-N-hydroxysuccinimide ester sodium salt (Sulfo-
SMCC) were purchased from Sigma-Aldrich, St. Louis,
MI, USA. Additional materials include Annexin V (hu-
man recombinant, Abcam, Cambridge, MA, USA), cyclic
RGDyC peptide (cyclo (Arg-Gly-Asp-Tyr-Cys), GL Bio-
chem Ltd., Shanghai, China); Na99mTcO4 and Na
125I
(China Isotope & Radiation Corporation, Beijing, China);
Whatman 3MM chromatography paper (GE Healthcare
UK Limited, Buckinghamshire, UK), and BD Matrigel™
Basement Membrane Matrix. Diethylene triamine pen-
tacetate acid (DTPA), amine-PEG-thiol (MW = 3 kDa,
1,500 equivalents), analytical phosphate-buffered saline
(PBS; 0.2 M), SnCl2 · 2H2O, and acetone were pur-
chased from China National Pharmaceutical Group
Corporation, Beijing, China. 99mTc-DTPA-Annexin V
was prepared in-house following the reported method
with radiochemical purity >95% [29].Animal models
All animal experiments were approved by the Tianjin
Medical University Cancer Institute and Hospital Ani-
mal Care Committee and were in accordance with the
ethical guidelines of the National Institutes of Health.
All efforts were made to minimize animal suffering and
the number of animals that were used. Twenty BALB/C
mice (male, 10 weeks, weight of 20 ± 1 g each) were pro-
vided by the Institute of Laboratory Animal Science,
CAMS. Mice were raised in a SPF class experimental
animal room. 5 × 106 cells (in 30 μL Matrigel) were sub-
cutaneously injected into the right hind leg to prepare
the NCI-H466 tumor model mice. Tumor-bearing mice
were ready for treatment when tumor volume reached
80 to 100 mm3 (10 to 14 days needed).
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In a three-necked flask with reflux unit, HAuCl4 was
dissolved in 50 mL distilled water at a concentration of
0.1 mg/mL and then heated to 100°C. One milliliter of
10 mg/mL sodium citrate solution was added, and the
reaction lasted for another 5 min. The reaction system
was naturally cooled down to room temperature, and
the product was collected with a 10,000 nominal mo-
lecular weight limit centrifugal filter units. Gold nano-
particles were stored at a concentration of 1 mg/mL.
Surface modification followed the reported procedures
with some improvements [25,30]: (i) GNPs were pre-
treated with Tween 20. Tween 20 (0.1 mL) was added to
10 mL of GNPs and then stirred for 10 min. (ii) After
the addition of 1 mL amine-PEG-thiol, the mixture was
stirred for 2 h to allow complete binding between GNPs
and thiol groups. The mixture was purified by centrifu-
gation twice (10,000 rpm for 10 min, at 4°C, hereinafter
the same below). The product was redispersed in 10 mL
HEPES buffer (0.3 M, pH = 8.0). (iii) Sulfo-SMCC was
linked to the amine part of PEG-coated GNPs. Freshly
dissolved sulfo-SMCC (1 mL, 100 μM, in DMSO) was
added to the suspension above. The mixture was vor-
texed for 1 h and then purified by centrifugation twice.
(iv) For cyclic RGDyC peptide conjugation, the super-
natant was redispersed in 10 mL of cyclic RGDyC pep-
tide (100 μM) in PBS (pH = 7.4) and then vortexed for
1 h. cRGD-GNPs was harvested after centrifugation and
kept at 4°C and in dark condition for long-term storage.
(v) Iodine labeling was performed before the in vivo ap-
plications. Na125I (370 MBq) and iodogen (20 μg) were
added into the above cRGD-GNP suspension (containing
10-mg GNPs). The reaction lasted for 10 min at roomFigure 1 Schematic synthesis procedure of 125I-cRGD-GNPs and chang
nanoparticles includes PEG covering, surface modification, cyclic RGD conjutemperature. The schematic synthesis procedure is de-
scribed in Figure 1.
The morphology and size of GNPs were characterized
using TEM at an acceleration voltage of 200 kV; UV
absorbance of nude GNPs was measured to detect max-
imum absorption peak, and UV spectrums of liquid super-
natant of cRGD conjugation reaction system were obtained
before and after the reaction to confirm the conjugation of
cRGD. The size distribution of PEG-coated GNPs was mea-
sured by dynamic light scattering (DLS); measurement of
surface ζ potential was performed by zetasizer to evaluate
the PEG covering and cRGD coupling. The in vitro stability
of 125I-cRGD-GNPs was tested by incubating 125I-cRGD-
GNPs in 0.05 M PBS or 10% fetal bovine serum (FBS) for
3 days at 37°C. Radiolabeling efficiency and radio-chemical
purity were monitored by thin-layer chromatography
silica-gel-based thin-layer chromatography with 0.9%
NaCl as developing solvent: Rf of
125I-cRGD-GNPs is
0 and Rf of I-125 is 1.
Investigation of biodistribution
I-125-labeled cRGD-GNPs (37 MBq, containing 1-mg
GNPs) were injected intravenously. At 1, 2, and 4 h post
injection, mice were anesthetized via 2% isoflurane in-
halation. SPECT was performed with the following pa-
rameters: four high-resolution, conical collimators with
nine-pinhole plates; energy peak, 28 keV; window width,
10%; resolution, 1 mm/pixel; matrix, 256 × 256; and scan
time, 60 s/projection with 24 projections in all. Three-
dimensional ordered subset expectation maximization
images were reconstructed using HiSPECT (Bioscan,
Washington D.C., USA). CT was then performed with
the following scan parameters: frame resolution, 256 ×es of surface ζ potential. The schematic procedure of hybrid
gation, and I-125 labeling.
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time, 500 ms/frame. Real-time 3D reconstructions of the
collected images were performed using the Nucline soft-
ware (v 1.02, Mediso, Hungary). A fused SPECT/CT
image was generated for investigation of biodistribution.
Drug residual was inspected by the radioactivity meter,
and the radioactivity of excreta was recorded by the γ coun-
ter as well to detect the metabolic pathways. A value lower
than 2.5% of the injected dosage was deemed as roughly
cleared. Samples of blood, urine, and feces were collected
immediately after injection and at 0.5, 1, 2, 4, and 10 h and
1, 2, and 3 days post injection and then measured by the γ
counter to investigate the %ID/g. All the recorded data of
radioactivity was corrected to the original injected radio-
activity dosage.
Radiotherapy of tumor-bearing mice
Twenty NCI-H466 tumor-bearing mice were divided
into five groups for treatments: 125I-cRGD-GNPs with
radiotherapy, cRGD-GNPs with radiotherapy, GNPs with
radiotherapy, radiotherapy alone, and control group (no
treatment). Injections were sterilized by 0.22-μm filter
membrane. For the radiosensitized radiotherapy, 100 μL
(containing 1-mg Au) 125I-cRGD-GNPs, cRGD-GNPs, or
GNPs were injected intravenously. At the definite time,
mice were anesthetized via intraperitoneal injection of
150 μL 4% chloral hydrate. Tumor tissues were exposed
to 5-Gy γ rays emitted by the Co-60 source. The injected
doses were normalized to about 50-μg GNPs every gram
body weight.
Investigation of therapeutic effect
Two days after treatment, 99mTc-Annexin V (18.5 MBq/
mouse) was administered intravenously for apoptosis
evaluation. At 2 h after the injection, mice were anesthe-
tized via 2% isoflurane inhalation. SPECT was performed
using the following parameters: four high-resolution,
conical collimators with nine-pinhole plates; energy peak,
140 keV; window width, 10%; resolution, 1 mm/pixel;
matrix, 256 × 256; and scan time, 60 s/projection with 24
projections in all. Target/non-target (T/NT) analysis fo-
cused on the treated tumor tissues and corresponding
comparison to the tissues on the left leg.
For assessments of long-term influence, tumor sizes
were measured every 3 days (during early stage) or every
6 days (during later stage) and calculated as follows:
Volume = (Tumor length) × (Tumor width)2/2. The body
weight of every mouse was recorded as well. Mice were
sacrificed at the 21st day after treatment, and the weight
of excised tumors was recorded.
Statistics
Data of volume and weight were expressed as mean ±
standard deviation (SD). One-way (treatment method)analysis of variance (ANOVA) followed by post hoc test
was used to analyze the differences between groups.
Statistics were performed in SPSS 19.0.
Results and discussion
Synthesis of 125I-cRGD-GNPs
The as-synthesized GNPs were of a uniform size of 21.7 ±
2.1 nm, and the maximum UV absorption peak was at
537 nm. DLS hydrodynamic diameter of PEG-covered
GNPs was 45.2 ± 2.6 nm. cRGD was successfully con-
jugated to GNPs based on the changes of surface ζ
potential and RGD concentration changes of reaction
supernate reflected by the UV spectrum. The surface ζ
potentials of 125I-cRGD-GNP synthesis after every step
are marked in Figure 1.
For radionuclide labeling, the labeling rate was 86.3% ±
2.4%; radiochemical purity was more than 99% after centri-
fugation. I-125-labeled cRGD-GNPs was stable in vitro,
with a stability of 86.2% ± 1.7% in PBS and 76.3% ± 1.6% in
10% FBS at 3 days after labeling. These guaranteed the long
period work of this hybrid nanoparticle system. 125I-cRGD-
GNPs were water-soluble and wine red. The morph-
ology of GNPs, solution status, and details of stabilities
are shown in Figure 2.
In vivo biodistribution
In vivo biodistribution of cRGD-GNPs was shown by
SPECT/CT images (Figure 3A). Attributing to the PEGs
covering and cyclic RGD conjugation, cRGD-GNPs tar-
geted tumor more efficiently and avoided heavy capture
by the liver, while part of the nanoparticles were still
absorbed by the gallbladder. cRGD-GNPs were expelled
from the blood system rapidly and targeted tumor with
a peak value of T/NT of 4.76 at 2 h post injection. T/
NT remained 4.25 at 4 h post injection. cRGD-GNPs
were mainly expelled via the kidney during the first 4 h.
cRGD-GNPs were also absorbed by the intestine and
then expelled gradually during the first 2 days. The de-
tailed changes of radioactivity of the blood, urine, and
feces are plotted in Figure 3B, C. Based on the mechan-
ism of 125I-cRGD-GNPs, radiotherapy treatments were
performed at 4 h post injection with a relatively high
T/NT value of 4.25, a precondition of valid radiosensi-
tive RT. Meanwhile, radiosensitized RT-induced damage
to normal tissues was controlled to a relatively low level
at 4 h post injection. Dynamic monitoring of radioactiv-
ity proved that only less than 2.5% radioactivity residual
was detected at 55 h post injection (Figure 3D). Herein,
assessment of apoptosis based on 99mTc-Annexin V
SPECT was performed at 2 days post treatment to
reflect the therapeutic effect in acute period.
For tumor-targeted agents, an ideal delivery of nano-
particles to tumor tissues will preferentially increase
tumor cytotoxicity and minimize damage to healthy
Figure 2 Characterization of 125I-cRGD-GNPs. (A) TEM of nude gold nanoparticles. (B) UV spectrum of GNPs. (C) In vitro stabilities of I-125 labeling in
PBS and FBS solution. (D) Status of 125I-cRGD-GNP injection.
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to facilitate the targeted accumulation of gold nanopar-
ticles, such as the introduction of anti-EGFR antibody
[31,32]. Based on a similar mechanism, RGD conjuga-
tion approach utilized active angiogenesis targeting as
well; furthermore, the rigidity of cyclic RGDyC and
unique expression of αvβ3 integrin in blood tumor ves-
sels guarantee the persistence, specificity, and high ef-
ficiency of radiosensitizer. On the other side, particle
size and surface covering is an important role in deter-
mining the clearance. Smaller size and biocompatible
materials, such as glutathione [33], are contributing
factors in enhancing EPR effect. In this research, func-
tionalized PEG was used and exhibited an appreciating
stability and clearance, avoiding abundant uptake by RES.
Besides these, the versatility of functionalized PEG provides
multiple potential for modification of particles.
Radiosensitized therapeutic effect
Apoptosis is one of the main RT-induced responses in
early stage. Annexin V specially targets the phosphatidyl-
serine located on the surface of apoptotic tumor cells.
Therefore, apoptosis degree detected by 99mTc-Annexin
V SPECT closely correlated to the therapeutic effect in-
duced by radiosensitized RT. As reflected by T/NTvalues (Figure 4), which indicated the degree of apop-
tosis, therapeutic effects resulting from the introduction
of targeted radiosensitizers were more serious than those
from radiotherapy alone, as well as the control group,
where slight apoptosis resulted from the inflammatory
tumor tissues. Although there was not a significant dif-
ference between 125I-cRGD-GNPs-based RT and cRGD-
GNPs-based RT (for T/NT, 11.2 ± 2.1 vs 9.8 ± 2.7, P =
0.093), significant differences were exhibited between
targeted radiosensitizer-based RT and non-targeted
radiosensitizer-based RT (for T/NT, 9.8 ± 2.7 vs 5.5 ± 1.4,
P = 0.011) and between radiolabeled cRGD-GNPs-based
RT and non-targeted radiosensitizer-based RT (for T/
NT, 11.2 ± 2.1 vs 5.5 ± 1.4, P < 0.01). On the one side, ra-
diosensitive effect were totally shown via 99mTc-Annexin
V SPECT for apoptosis; on the other side, targeting ef-
fect enhanced radiosensitive effect effectively.
Long-term observation showed the therapeutic effect
of radiosensitized RT directly via tumor volume changes
(Figure 5A). On day 21, the increase of tumor volume of
mice treated by RT with targeted radiosensitizer was
suppressed to 33.1% ± 17.1%. 125I-cRGD-GNPs even lead
a less increase of 15.2% ± 17.8%. Volume increases of
the groups of GNPs with RT, RT alone, and control
were 85.5% ± 44.2%, 137.1% ± 35.5%, and 312.1% ±
Figure 3 In vivo mechanism of 125I-cRGD-GNPs. (A) SPECT/CT images of tumor-bearing mice at 1, 2, and 4 h post injection; tumor tissues were
circled and T/NT values were marked. (B) Changes of %ID/g of metabolins from the kidney and intestine. (C) Concentration change of radiosensitizer in
the blood. (D) In vivo retained amount of targeted radiosensitizer reflected by retained radioactivity.
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of excised specimen of tumor tissues were 0.116 ± 0.022
(125I-cRGD-GNPs, RT), 0.113 ± 0.019 (cRGD-GNPs, RT),
0.171 ± 0.041 (GNPs, RT), 0.209 ± 0.038 (RT only), and
0.538 ± 0.102 g (no treatment), respectively. Additionally, noobvious weight loss of mice was observed (Figure 5C),
indicating a low in vivo toxicity of PEG-covered GNPs
and cRGD-GNPs.
Apoptosis and necrosis are the primary approach of
radiotherapy-induced cell death, which related to a series
Figure 4 T/NT values of five groups, indicating the degree of
apoptosis. Significant targeted radiosensitizer-induced apoptosis
were observed from the group of ‘125I-cRGD-GNPs with RT’ and
‘cRGD-GNPs with RT’.
Figure 5 Long-term evaluation of radiosensitive RT effect. (A)
Changes of tumor volumes at a definite time post injection. (B) Weight
of excised tumor tissues at the 21st day. (C) Body weight changes of
tumor-bearing mice.
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break of DNA and mitochondrial damage [34,35].
Apoptosis imaging is an innovative strategy in the
pathogenesis detection and early therapeutic effect
evaluation, such as tumor response to chemotherapy
and radiotherapy [36]. In this research, 99mTc-Annexin
V SPECT after radiotherapy, but the commonly used
in vitro test, such as TUNEL staining and γ-H2AX
assay of DNA double-strand break, were utilized, avoiding
the separate characterization of apoptosis and long-term
therapeutic effect. When considering apoptosis and
long-term volume change together, we found that there
are a kind of connection and a predicting significance of
apoptosis for long-term therapeutic effect. Hence, 99mTc-
Annexin V SPECT provides an approach of early evalu-
ation of radiosensitized radiotherapy.
For a better understanding of radiosensitizing effect of
GNPs, such as the detailed biodistribution, some efforts
have been made emphasizing on the in vivo tracking.
Different with the introduction of MRI-detectable gado-
linium chelates [37], the introduction of I-125 provided
a signal closely correlated with the concentration of
cRGD-GNPs. Therapeutic effect of I-125 was shown,
but not a statistically significant improvement when
compared with cRGD-GNP group. Therapeutic effect
of radionuclide may be heavily enhanced if a more ef-
fective radionuclide, such as I-131, was chosen. On
the other hand, based on the point of view that ‘expos-
ure of tumors to irradiation causes transient upregula-
tion of αvβ3 on tumor blood vessel endothelium’
[38,39], cRGD targeting may be enhanced by upregu-
lation of αvβ3 resulting from the introduction of
iodine-125 [40]. So, radionuclide plays roles as a ra-
diotracer, a therapeutic factor, as well as a contributing
factor for targeting.Conclusions
In this research, I-125-labeled cRGD-GNPs were suc-
cessfully synthesized for targeting tumor tissues. Tumor
uptake of cRGD-GNPs reached the peak T/NT value at
2 h post injection. For therapeutic effect, 125I-cRGD-
GNPs were of a high radiotherapy efficiency due to the
radiosensitive property of gold nanoparticles, as well
as the introduction of αvβ3-targeted molecule and radio-
nuclide. This study demonstrated that 50-μg GNPs
every gram body weight in combination with 5-Gy γ ray
Su et al. Nanoscale Research Letters  (2015) 10:160 Page 8 of 9radiotherapy at 4 h post injection resulted in effective
suppression of tumor growth. These results have important
implications in developing radionuclide-labeled radiosensi-
tizer for enhanced radiotherapy.
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